• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial.
Abstract Tobacco smoking is a global pandemic that poses substantial health burdens and costs. With nearly six million deaths annually, smoking is the single most important cause of avoidable premature mortality in the world, mainly from lung cancer, coronary heart disease, chronic obstructive pulmonary disease and stroke. Smoking is a very difficult addiction to break, even for those with a strong desire to quit. Electronic cigarettes are an attractive long-term alternative source of nicotine to conventional cigarettes because of their many similarities with smoking. Electronic cigarette users report buying them ...
Source: Clinical Lung Cancer - August 8, 2019 Category: Cancer & Oncology Authors: Caponnetto P, Maglia M, Polosa R Tags: Contemp Clin Trials Commun Source Type: research

Cost ‐effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD
ConclusionsAccording to the EQUIPTMOD modelling tool it would be cost‐effective for the Spanish authorities to expand the reach of existing GP brief interventions for smoking cessation, provide pro‐active telephone support, and reimburse smoking cessation medication to smokers trying to stop. Such policies would more than pay for themselves in the long run.
Source: Addiction - March 13, 2018 Category: Addiction Authors: Marta Trapero ‐Bertran, Celia Muñoz, Kathryn Coyle, Doug Coyle, Adam Lester‐George, Reiner Leidl, Bertalan Németh, Kei‐Long Cheung, Subhash Pokhrel, Ángel Lopez‐Nicolás Tags: Research Report Source Type: research

Estimates of costs for modelling return on investment from smoking cessation interventions
ConclusionsCosts of treating smoking‐attributable diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary, Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to return on investment estimates in support of national or regional policy decisions.
Source: Addiction - March 13, 2018 Category: Addiction Authors: Marta Trapero ‐Bertran, Reiner Leidl, Celia Muñoz, Puttarin Kulchaitanaroaj, Kathryn Coyle, Maximilian Präger, Judit Józwiak‐Hagymásy, Kei Long Cheung, Mickael Hiligsmann, Subhash Pokhrel, Tags: Research Report Source Type: research

Delayed Varenicline Administration Reduces Inflammation and Improves Forelimb Use Following Experimental Stroke
Pharmacological activation of the cholinergic anti-inflammatory pathway (CAP), specifically by activating α7 nicotinic acetylcholine receptors, has been shown to confer short-term improvements in outcome. Most studies have investigated administration within 24 hours of stroke, and few have investigated drugs approved for use in human patients. We investigated whether delayed administration of varenicli ne, a high-affinity agonist at α7 nicotinic receptors and an established therapy for nicotine addiction, decreased brain inflammation and improved functional performance in a mouse model of experimental stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - August 7, 2017 Category: Neurology Authors: Siyi Chen, Laura Bennet, Ailsa L. McGregor Source Type: research

How to Quit Smoking
By Stacy Simon Tobacco use remains the single largest preventable cause of disease and premature death in the United States. Since the release of the Surgeon General’s Report on Smoking and Health 50 years ago, there have been 20 million deaths due to tobacco. Almost half the deaths from 12 different types of cancer combined – including lung, voice box, throat, esophagus, and bladder cancers – are attributable to cigarette smoking alone. In addition to cancer, smoking greatly increases the risk of debilitating long-term lung diseases like emphysema and chronic bronchitis. It also raises the risk for heart...
Source: American Cancer Society :: News and Features - November 16, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

Study: Nicotine Patch Works as Well as Chantix to Help Quit Smoking
This study confirms that FDA-approved medications are effective in helping smokers quit,” said Lee Westmaas, PhD, American Cancer Society director of tobacco control research. “Smokers should seriously consider using medications if they are finding it difficult to quit without any help. The most effective approach to quitting is using medications in combination with counseling such as from a quit-line.”RESOURCES: How to Quit Smoking Quit-smoking medicationsResearch shows that using a medication to help you quit smoking can double your chances of being successful.The US Food and Drug Administration (...
Source: American Cancer Society :: News and Features - February 2, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

'No serious heart risks' linked to smoking cessation therapies
The American Heart Association claims that three different types of smoking cessation therapies do not pose serious heart risks, quashing concerns that certain products may increase the risks of heart attack, stroke or heart-related death.Researchers looked at the results of 63 clinical trials involving 30, 508 people who were quitting smoking using either nicotine replacement gums and patches, the nicotine addiction treatment varenicline (Chantix), or taking the antidepressant bupropion (Wellbutrin), which can reduce cravings and other unwanted withdrawal effects.
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Smoking / Quit Smoking Source Type: news